Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

(2015) Thomas Cluzeau et al.   Oncotarget

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

(2013) R. Z. Mahfouz et al.   CLINICAL CANCER RESEARCH

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

(2013) F Traina et al.   LEUKEMIA

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells

(2012) Yuriko Saiki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

(2012) J. Aimiuwu et al.   BLOOD

Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine

(2012) Francesca Buchi et al.   LEUKEMIA RESEARCH

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

(2011) M T Voso et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome

(2011) Taichun Qin et al.   PLoS One

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines

(2010) S K Rathe et al.   LEUKEMIA

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

(2010) M Y Follo et al.   LEUKEMIA

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

(2010) Paul W. Hollenbach et al.   PLoS One

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation

(2009) M. Rius et al.   MOLECULAR CANCER THERAPEUTICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

(2009) M. Y. Follo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes

(2009) Valeria Santini   Expert Review of Hematology

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

(2008) Carlo Stresemann et al.   INTERNATIONAL JOURNAL OF CANCER